Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.

Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E. · 2020

Read Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. by Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7574912.txt.

Introduction

Chan and co-authors engineer human ACE2 to bind the SARS-CoV-2 spike protein more tightly. The virus enters cells when spike binds ACE2. A soluble form of ACE2 could act as a decoy.

The team used deep mutagenesis to scan ACE2 variants. Mutants that bound spike more tightly were identified. Combining mutations raised binding strength further still. One variant was built as a stable dimer. Its binding matched that of neutralizing antibodies. It neutralized both SARS-CoV-2 and SARS-CoV-1 in cell tests. Likeness to the natural receptor may limit viral escape. The work offers a protein-based route to block infection at entry.

Catalog record

CREATORChan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7574912

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2 By Kui K Chan, Danielle Dorosky, Preeti Sharma, Shawn A Abbasi, John M Dye, David M Kranz, Andrew S Herbert, Erik Procko Published in: Science (New York, N.y.) DOI: 10.1126/science.abc0870 ABSTRACT A decoy receptor for SARS-CoV-2 For severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter human cells, the spike protein on the surface of the virus must bind to the host receptor protein, angiotensin-converting enzyme 2 (ACE2). A soluble version of the receptor is being explored as a therapeutic. Chan et al. used deep mutagenesis to identify ACE2 mutants that bind more tightly to the spike protein and combined mutations to further increase binding affinity (see the Perspective by DeKosky). A promising variant was engineered to be a stable dimer that has a binding affinity for the spike protein; it is comparable with neutralizing antibodies and neutralized both SARS-CoV-2 and SARS-CoV-1 in a cell-based assay. In addition, the similarity to the natural receptor may limit the possibility for viral escape. Science, this issue p. 1261; see also p. 1167 In late 2019, a novel zoonotic betacoronavirus closely related to bat coronaviruses crossed into humans in the Chinese city of Wuhan (1, 2). The virus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of its similarities with the SARS coronavirus first discovered in 2003 (3, 4), causes coronavirus disease 2019 (COVID-19) (5), which is producing devastation across the globe. The spike (S) glycoprotein of SARS-CoV-2 binds angiotensin-converting enzyme 2 (ACE2) on host cells (2, 6–11). S is a trimeric class I viral fusion protein that is proteolytically processed into S1 and S2 subunits that remain noncovalently associated in a prefusion state (6, 9, 12). Upon engagement of ACE2 by a receptor binding domain (RBD) in S1 (13), conformational rearrangements occur that cause S1 shedding, cleavage of S2 by host proteases, and exposure of a fusion peptide adjacent to the S2' proteolysis site (12, 14–16). Folding of S to a postfusion conformation is coupled to host cell–virus membrane fusion and cytosolic release of viral RNA. Atomic contacts with the RBD are restricted to the extracellular protease domain of ACE2 (17, 18). Soluble ACE2 (sACE2) in which the transmembrane domain has been removed is sufficient for binding S and neutralizing infection (10, 19–21). A broad collection of highly potent neutralizing antibodies have been isolated (22–28), yet the virus spike shows rapid accumulation of escape mutations when under selection (29). By comparison, the virus may have limited potential to escape sACE2-mediated neutralization without simultaneously decreasing affinity for native ACE2 receptors, an outcome that is likely to attenuate virulence. Furthermore, sACE2 could potentially treat COVID-19 symptoms by proteolytic conversion of angiotensin peptides that regulate blood pressure and volume (30, 31). Recombinant sACE2 is safe in healthy human subjects (32) and patients with lung disease (33), and is being evaluated in a European phase 2 clinical trial for COVID-19 managed by Apeiron Biologics. Peptide derivatives of ACE2 are also being explored as cell entry inhibitors (34). Because human ACE2 has not evolved to recognize SARS-CoV-2 S, we hypothesized that mutations may be found that increase affinity. The coding sequence of full-length ACE2 with an N-terminal c-MYC epitope tag was diversified to create a library containing all possible single–amino acid substitutions at 117 sites that span the interface with S and the angiotensin peptide-binding cavity. S binding is independent of ACE2 catalytic activity (35) and occurs on the outer surface of ACE2 (17, 18), whereas angiotensin substrates bind within a deep cleft that houses the active site (36). The ACE2 library was transiently expressed in human Expi293F cells under conditions that typically yield no more than one coding variant per cell, providing a tight link between genotype and phenotype (37, 38). Cells were then incubated with a subsaturating dilution of medium containing the RBD of SARS-CoV-2 fused to superfolder green fluorescent protein [sfGFP; (39)] (fig. S1A). Dual-color flow cytometry measurements show that amounts of bound RBD-sfGFP correlate with surface expression levels of MYC-tagged ACE2. Compared with cells expressing wild-type ACE2 (fig. S1C), many variants in the ACE2 library fail to bind RBD, whereas a smaller number of ACE2 variants showed higher binding signals (fig. S1D). Populations of cells that express ACE2 variants at the cell surface with high (“nCoV-S-High”) or low (“nCoV-S-Low”) binding to RBD were collected by fluorescence-activated cell sorting (FACS) (fig. S1D). During FACS, the fluorescence signal for bound RBD-sfGFP continuously declined, requiring the collection gates to be regularly updated to “chase” the relevant populations. This is consistent with RBD dissociating during the experiment. In an approach known as deep mutagenesis (40), the enrichment or depletion of all 2340 coding mutations in the library was determined by comparing the frequencies of transcripts in the sorted populations to sequence frequencies in the naïve plasmid library (Fig. 1A). Enrichment ratios and residue conservation scores closely agree between two independent FACS experiments (fig. S2). Enrichment ratios and conservation scores in the nCoV-S-High sorted cells tend to be negatively correlated with the nCoV-S-Low sorted cells, with the exception of nonsense mutations that do not express and were therefore depleted from both populations (fig. S2). Most, but not all, nonsynonymous mutations in ACE2 did not eliminate surface expression (fig. S2). The library is biased toward solvent-exposed residues and has few substitutions of buried hydrophobic residues that might have greater effects on plasma membrane trafficking (38). [Figure: Sequence preferences of ACE2 residues for high binding to the RBD of SARS-CoV-2 S.(A) Log2 enrichment ratios from the nCoV-S-High sorts are plotted from depleted or deleterious (orange) to enriched (dark blue). ACE2 primary structure is shown on the vertical axis, amino acid substitutions are indicated on the horizontal axis. Wild-type amino acids are in black. Asterisk (*) denotes stop codon. (B) Conservation scores are mapped to the structure (Protein Data Bank 6M17) of RBD (green ribbon)–bound protease domain (surface), oriented with the substrate-binding cavity facing the reader. Residues conserved for RBD binding are shown in orange; mutationally tolerant residues are in pale colors; residues that are hot spots for enriched mutations are in blue; and residues maintained as wild type in the ACE2 library are in gray. Glycans are depicted as dark red sticks. (C) Viewed looking down on to the RBD interaction surface. (D) Average hydrophobicity-weighted enrichment ratios are mapped to the structure, with residues tolerant of polar substitutions in blue and residues that prefer hydrophobics in yellow. (E) A magnified view of the ACE2–RBD interface [colored as in (B) and (C)]. Heat-map plots log2 enrichment ratios from the nCoV-S-High sort. Abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.] Mapping the experimental conservation scores from the nCoV-S-High sorted cells to the structure of RBD-bound ACE2 (17) shows that residues buried in the interface tend to be conserved, whereas residues at the interface periphery or in the substrate-binding cleft are mutationally tolerant (Fig. 1, B and C). The region of ACE2 surrounding the C-terminal end

Read the complete text